Fraiser Kansteiner
Fierce Pharma contributor who reported on Lilly's retatrutide (triple agonist) data and discussed clinical results and tolerability in the diabetes and obesity context.
Best podcasts with Fraiser Kansteiner
Ranked by the Snipd community
16 snips
Mar 27, 2026 • 16min
Pulse check on Lilly's GLP-1 fortunes
Fraiser Kansteiner, Fierce Pharma reporter who covered Lilly’s retatrutide data, and Kevin Dunleavy, Fierce Pharma industry reporter, discuss Lilly’s recent HSBC downgrade and market fallout. They dive into retatrutide’s diabetes and weight-loss data, tolerability questions, competitive risks from Novo and generics, and what the regulatory and commercial timeline might mean for GLP-1 positioning.
14 snips
Aug 15, 2025 • 26min
The battle of the obesity drug heavyweights
Fraiser Kansteiner, a journalist from Fierce Pharma, joins to unravel the fierce competition between Novo Nordisk and Eli Lilly in the obesity drug market. They discuss Novo's challenges, including product shortages and a recent pipeline clearout. Kansteiner highlights Lilly’s successful strategies amidst increasing sales and the implications of compounding pharmacies. The conversation also touches on Pfizer's exit from the obesity race and the potential emergence of smaller biotech firms, painting a vivid picture of the evolving landscape.
